Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Y-MABS THERAPEUTICS, INC.

(YMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about Y-MABS THERAPEUTICS, INC.
01/05Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
AQ
01/03JPMorgan Adjusts Y-mAbs Therapeutics' Price Target to $27 from $30, Keeps Neutral Ratin..
MT
2021Y MABS THERAPEUTICS : Management Change/Compensation - Form 8-K
PU
2021Y-mAbs Therapeutics, Inc. Announces Appointment of Sue Smith as Chief Commercial Office..
CI
2021UPDATE - Y-mAbs Announces Pipeline Update
GL
2021Y MABS THERAPEUTICS : mAbs Announces Pipeline Update - Form 8-K
PU
2021Y-mAbs Announces Pipeline Update
AQ
2021INSIDER SELL : Y-mAbs Therapeutics
MT
2021Y-mAbs Hosting Virtual Research and Development Day
GL
2021Y-mAbs Hosting Virtual Research and Development Day
GL
2021INSIDER SELL : Y-mAbs Therapeutics
MT
2021INSIDER SELL : Y-mAbs Therapeutics
MT
2021Y-mAbs Therapeutics, Inc. Announces Executive Changes
CI
2021Y-mAbs Therapeutics Downgraded, Price Target Cut at JPMorgan
MT
2021JPMorgan Cuts Y-mAbs Therapeutics to Neutral From Overweight, Price Target to $30 From ..
MT
2021Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments - Fo..
PU
2021Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q3 Revenue $9M, vs. Street Est of $10.9..
MT
2021Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments
AQ
2021Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
CI
2021Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neur..
PU
2021Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neur..
AQ
2021Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neur..
CI
2021Y-mAbs to Announce Third 2021 Financial and Operating Results on November 4, 2021
AQ
2021INSIDER SELL : Y-mabs Therapeutics
MT
2021Y MABS THERAPEUTICS : mAbs 177Lu-omburtamab-DTPA for the Treatment of Patients with Medull..
AQ
2021Y MABS THERAPEUTICS : Gets FDA's Rare Pediatric Disease Designation for Potential Therapy ..
MT
2021Y MABS THERAPEUTICS : mAbs' 177Lu-omburtamab-DTPA for the Treatment of Patients with Medul..
PU
2021Y MABS THERAPEUTICS : mAbs' 177Lu-omburtamab-DTPA for the Treatment of Patients with Medul..
AQ
2021U.S. Food and Drug Administration Grants Rare Pediatric Disease Designation for Y-mAbs’..
CI
2021INSIDER SELL : Y-mabs Therapeutics
MT
2021INSIDER SELL : Y-mabs Therapeutics
MT
2021Y MABS THERAPEUTICS : mAbs Announces Data to be Presented at SIOP 2021
AQ
2021Y MABS THERAPEUTICS : mAbs Announces Priorit Review of BLA for DANELZA (naxitamab-gqgk) in..
AQ
2021Y MABS THERAPEUTICS : mAbs-Licensed Danelza Granted Priorit Review b Chinese Regulator; Sh..
MT
2021Y MABS THERAPEUTICS : mAbs Announces Priorit Review of BLA for DANELZA« (naxitamab-gqgk) i..
PU
2021Y MABS THERAPEUTICS : mAbs to Host Ke Opinion Leader Webinar on DANELZA (naxitamab-gqgk) F..
AQ
2021Y MABS THERAPEUTICS : mAbs Announces Priorit Review of BLA for DANELZA« (naxitamab-gqgk) i..
AQ
2021Y-Mabs Therapeutics, Inc. Announces Priority Review of BLA for DANYELZA« (Naxitamab-Gqg..
CI
2021Y MABS THERAPEUTICS : mAbs to Host Ke Opinion Leader Webinar on DANELZA« (naxitamab-gqgk) ..
AQ
2021INSIDER SELL : Y-mabs Therapeutics
MT
2021Y MABS THERAPEUTICS : Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q2 Revenue $11M, vs...
MT
2021Y MABS THERAPEUTICS : mAbs Announces Second Quarter Financial Results and Recent Corporate..
AQ
2021Y-Mabs Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30..
CI
2021Y-mAbs to Announce Second Quarter 2021 Financial and Operating Results on August 5, 202..
GL
2021Y MABS THERAPEUTICS : mAbs Announces NMPA Submission of BLA for DANELZA (naxitamab-gqgk) i..
AQ
2021Y MABS THERAPEUTICS : Partner SciClone Seeks China Approval of Danyelza for High-Risk Neur..
MT
2021Y MABS THERAPEUTICS : mAbs Announces NMPA Submission of BLA for DANELZA« (naxitamab-gqgk) ..
PU
2021Y-mAbs Announces NMPA Submission of BLA for DANYELZA« (naxitamab-gqgk) in China
GL
2021Y-mAbs Therapeutics, Inc. Announces NMPA Submission of BLA for DANYELZA« (naxitamab-gqg..
CI
2021Y MABS THERAPEUTICS : HC Wainwright Adjusts Price Target on Y-mAbs Therapeutics to $68 Fro..
MT
2021Y MABS THERAPEUTICS : EMA Panel Backs Issuance of Orphan Product Designation for Y-mAbs Th..
MT
2021Y-mAbs Therapeutics, Inc. Announces That the Committee for Orphan Medicinal Products of..
CI
2021Y-mAbs' 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Receiv..
GL
2021Y-mAbs Therapeutics Gets OMPD in E.U. for Medulloblastoma Treatment
DJ
2021Y MABS THERAPEUTICS : mAbs' 177Lu-omburtamab-DTPA for the Treatment of Patients with Medul..
PU
2021Y MABS THERAPEUTICS : to Start Rolling Resubmission of FDA Biologics License Application f..
MT
2021Y MABS THERAPEUTICS : mAbs Provides Regulator Update on Omburtamab for the Treatment of Pa..
PU
2021Y MABS THERAPEUTICS : mAbs Provides Regulator Update on Omburtamab for the Treatment of Pa..
AQ
2021Y-mAbs Therapeutics, Inc. Provides Regulatory Update on Omburtamab for the Treatment of..
CI
2021Y MABS THERAPEUTICS : mAbs Announces Frontline Data for DANELZA (naxitamab-gqgk) in High-R..
AQ
2021Y MABS THERAPEUTICS : mAbs Announces Update on Omburtamab for DIPG
AQ
2021Y MABS THERAPEUTICS : Discloses Presentation of Phase 1 Data on Omburtamab
MT
2021Y MABS THERAPEUTICS : Press Release, dated June 4, 2021 issued by Y-mAbs Therapeutics, Inc..
PU
2021Y MABS THERAPEUTICS : mAbs Announces Update on Omburtamab for DIPG (Form 8-K)
PU
2021Y-Mabs Announces Frontline Data for Danyelza« (Naxitamab-Gqgk) in High-Risk Neuroblasto..
CI
2021Y-mAbs Announces Frontline Data for DANYELZA« (naxitamab-gqgk) in High-Risk Neuroblasto..
GL
2021Y MABS THERAPEUTICS : mAbs Announces Update on Omburtamab for DIPG
AQ
2021Y-mAbs Therapeutics, Inc Announces Update on Omburtamab for DIPG
CI
2021MEDULLOBLASTOMA PIPELINE : Emerging Therapies and Key pharma players involved by DelveInsi..
AQ
2021Y MABS THERAPEUTICS : mAbs Enters into Exclusive Distribution Agreement with Adium Pharma ..
AQ
2021Y-mAbs Therapeutics Signs Exclusive Deal With Adium Pharma for Danyelza, Omburtamab Dis..
MT
2021Y MABS THERAPEUTICS : mAbs Enters into Exclusive Distribution Agreement with Adium Pharma ..
PU
2021Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA..
GL
2021Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA..
CI
2021Certain Common Stock of Y-mAbs Therapeutics, Inc. are subject to a Lock-Up Agreement En..
CI
1  2  3  4Next
Upcoming event on Y-MABS THERAPEUTICS, INC.
03/25/22